Leiden Bio Science Park

NecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technology

Retrieved on: 
Tuesday, September 19, 2023
Tissue, LV, Center for Cell and Gene Therapy, Gene, Leiden Bio Science Park, Proteon Therapeutics, AAV, CDMO, Patient, Cell, Vaccine

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.

Key Points: 
  • LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.
  • Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes.
  • We will continue our efforts aimed at improving AAV and LV vectors, catering to both transient production systems and stable viral producer cell lines".
  • ProteoNic will offer licensing and co-development opportunities, while NecstGen plans to apply the technology in its CDMO business.

NecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technology

Retrieved on: 
Tuesday, September 19, 2023
Tissue, LV, Center for Cell and Gene Therapy, Gene, Leiden Bio Science Park, Proteon Therapeutics, AAV, CDMO, Patient, Cell, Vaccine

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.

Key Points: 
  • LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ -- Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher titers of functional viral particles based on the application of ProteoNic's 2G UNic™ premium vector technology.
  • Both companies, located on the Leiden Bio Science Park, recognise the need to increase viral titres and optimise production processes.
  • We will continue our efforts aimed at improving AAV and LV vectors, catering to both transient production systems and stable viral producer cell lines".
  • ProteoNic will offer licensing and co-development opportunities, while NecstGen plans to apply the technology in its CDMO business.

High Performance Computing Global Market Report 2023: AI-powered HPC Market will Reach $37.4 Billion by 2028

Retrieved on: 
Thursday, March 16, 2023
Component, Computer-aided design, High-performance computing, D, Cloud, Deep learning, University, Intelligence, Research, Supercomputer, Computer, Government, Organization, Leiden Bio Science Park, HPC, Engineering, AI, Software, Medical device, Online shopping, Video game, Industrial design

The report also assesses the market for the integration of various artificial intelligence technologies in HPC.

Key Points: 
  • The report also assesses the market for the integration of various artificial intelligence technologies in HPC.
  • It also evaluates the exascale-level HPC market including analysis by component, hardware type, service type, and industry vertical.
  • The AI-powered HPC market will reach $37.4B globally by 2028, driven largely by simulations, engineering and design solutions.
  • High Performance Computing (HPC) may be provided via a supercomputer or via parallel processing techniques such as leveraging clusters of computers to aggregate computing power.

Global High Performance Computing Market to 2028: Simulations, Engineering and Design Solutions Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 16, 2023
Software, Technology, Hardware, Leiden Bio Science Park, Government, Research, University, Supercomputer, AI, HPC, D, Organization, Computer, Engineering, Online shopping, Video game, Industrial design

The AI-powered HPC market will reach $37.4B globally by 2028, driven largely by simulations, engineering and design solutions.

Key Points: 
  • The AI-powered HPC market will reach $37.4B globally by 2028, driven largely by simulations, engineering and design solutions.
  • High Performance Computing (HPC) may be provided via a supercomputer or via parallel processing techniques such as leveraging clusters of computers to aggregate computing power.
  • HPC is well-suited for applications that require high performance data computation such as certain financial services, simulations, and various R&D initiatives.
  • In an effort to identify growth opportunities for the HPC market, we investigated market gaps including unserved and underserved markets and submarkets.

Arcadis completes the acquisition of DPS Group, creating a leading position in the Life Sciences and Semiconductor manufacturing market

Retrieved on: 
Friday, December 2, 2022
Leiden Bio Science Park, Built environment, DPS, Engineering, Acquisition, Quality of life, Organization, IBI Group, Bristol Myers Squibb, Video game, Management, Arcadis

DPS (to be renamed as Arcadis DPS Group) will become part of Arcadis Places GBA, providing clients with a one-stop, full-service provider across the entire spectrum of the built environment.

Key Points: 
  • DPS (to be renamed as Arcadis DPS Group) will become part of Arcadis Places GBA, providing clients with a one-stop, full-service provider across the entire spectrum of the built environment.
  • The Irish headquartered business has a strong presence in North America and Europe, and long-standing client relationships with the worlds largest pharmaceutical and semiconductor manufacturing companies.
  • Simon Bimpson, currently leading Arcadis Resilience Business Area in the UK and Ireland will assume the role of President, Arcadis DPS Group, responsible for performance and integration.
  • The DPS acquisition showcases yet another significant milestone for Arcadis business of delivering a seamless and full service offering to clients.

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Retrieved on: 
Monday, September 12, 2022
Molecule, Leiden University Medical Center, Leiden University, Time, Safety, Trial of the century, Human, Ethics, Ketamine, University, LSD, DMT: The Spirit Molecule, Dream, Neurology, Company, Imperial College London, CHDR, Psilocybin, Growth, LUMC, Partnership, Stroke, Leiden Bio Science Park, Psychosis, IVF, Patient, Clinical trial, CSE, N,N-Dimethyltryptamine, AGN, Neurogenesis, Consciousness, Heart, Niacin, Pharmacokinetics, Pharmacy, Rehabilitation, GLOBE, DMT, Animal, Constraint-induced movement therapy, GMP, Brain, Pharmaceutical industry

Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.

Key Points: 
  • Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.
  • Christopher J. Moreau CEO of Algernon Pharmaceuticals further commented saying, We look forward to getting our DMT clinical stroke program started with our Phase 1 study at CHDR in the Netherlands, said.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.

ProteoNic and NecstGen establish partnership to improve viral vector manufacturing efficiency for Gene Therapies

Retrieved on: 
Tuesday, April 26, 2022
Gene, CEO, LV, CDMO, Acceleration, GMP, Patient, Proteon Therapeutics, Efficiency, AAV, Technology, Gene therapy, Solution, Unic, Center for Cell and Gene Therapy, Partnership, Leiden Bio Science Park, Cell, Vaccine, Pharmaceutical industry

Through their combined efforts ProteoNic and NecstGen aim to improve and advance AAV and LV viral vector manufacturing technology and increase production capacity, to the ultimate benefit of patients in need of Gene Therapies.

Key Points: 
  • Through their combined efforts ProteoNic and NecstGen aim to improve and advance AAV and LV viral vector manufacturing technology and increase production capacity, to the ultimate benefit of patients in need of Gene Therapies.
  • ProteoNic will apply its established 2G UNicTM technology platform to improve viral vector performance.
  • NecstGen, specialised in the manufacturing and development of various viral vector types, contributes its viral vector platforms, manufacturing processes and experts as part of this partnership.
  • We believe that together with NecstGen we can improve the production efficiency of viral vectors for Gene Therapy, and thereby alleviate current manufacturing constraints."

ProteoNic and NecstGen establish partnership to improve viral vector manufacturing efficiency for Gene Therapies

Retrieved on: 
Tuesday, April 26, 2022
Gene, CEO, LV, CDMO, Acceleration, GMP, Patient, Proteon Therapeutics, Efficiency, AAV, Technology, Gene therapy, Solution, Unic, Center for Cell and Gene Therapy, Partnership, Leiden Bio Science Park, Cell, Vaccine, Pharmaceutical industry

Through their combined efforts ProteoNic and NecstGen aim to improve and advance AAV and LV viral vector manufacturing technology and increase production capacity, to the ultimate benefit of patients in need of Gene Therapies.

Key Points: 
  • Through their combined efforts ProteoNic and NecstGen aim to improve and advance AAV and LV viral vector manufacturing technology and increase production capacity, to the ultimate benefit of patients in need of Gene Therapies.
  • ProteoNic will apply its established 2G UNicTM technology platform to improve viral vector performance.
  • NecstGen, specialised in the manufacturing and development of various viral vector types, contributes its viral vector platforms, manufacturing processes and experts as part of this partnership.
  • We believe that together with NecstGen we can improve the production efficiency of viral vectors for Gene Therapy, and thereby alleviate current manufacturing constraints."

Webcor and Reaume Richardson Form Strategic Alliance to Expand General Contracting Services in Southern California

Retrieved on: 
Wednesday, March 23, 2022
Dorado, LinkedIn, ROW DTLA, San Francisco Bay Area, The Hollywood Roosevelt Hotel, Leiden Bio Science Park, CEO, ROW, Construction, Industry, Twitter, GLOBE, RR, Bradbury Building, Instagram, Public relations, Webster-Chicago, Facebook

LOS ANGELES, March 23, 2022 (GLOBE NEWSWIRE) -- Webcor and Reaume Richardson are pleased to announce a strategic alliance to provide general contracting and construction management services for a variety of projects across the Southern California area.

Key Points: 
  • LOS ANGELES, March 23, 2022 (GLOBE NEWSWIRE) -- Webcor and Reaume Richardson are pleased to announce a strategic alliance to provide general contracting and construction management services for a variety of projects across the Southern California area.
  • The strategic alliance combines Reaume Richardson's long-standing history and client relationships in the Los Angeles adaptive reuse market with the large-scale resources of Webcor.
  • This alliance will allow Reaume Richardson to serve their clients with ground-up projects in the $100M+ range and for Webcor to leverage the historic, adaptive reuse acumen of the Reaume Richardson team.
  • "We have amazing client relationships built from 20+ years of work in downtown LA and beyond," says Bryson Reaume, founder and CEO of Reaume Richardson.

Global High Performance Computing Market 2022-2027: AI, IoT, and 5G will be Major Drivers for HPC Growth as they Facilitate the Need to Process Vast Amounts of Data - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 26, 2022
Software, Technology, Hardware, Data Management, Computer-aided design, Supercomputer, HPC, Software, AI, Government, Deep learning, Engineering, Cloud, University, National Center for High-Performance Computing, Leiden Bio Science Park, High-performance technical computing, D, Organization, Research, Intelligence, Solution, Computer, Price band, Component, Medical device, Online shopping, Industry

The High Performance Computing market includes computation solutions provided either by supercomputers or via parallel processing techniques such as leveraging clusters of computers to aggregate computing power.

Key Points: 
  • The High Performance Computing market includes computation solutions provided either by supercomputers or via parallel processing techniques such as leveraging clusters of computers to aggregate computing power.
  • It also evaluates the exascale-level HPC market including analysis by component, hardware type, service type, and industry vertical.
  • The AI-powered HPC market will reach $23.7B globally by 2026, driven largely by simulations, engineering and design solutions.
  • HPC is well-suited for applications that require high performance data computation such as certain financial services, simulations, and various R&D initiatives.